GEO series
B-cell depletion improves therapeutic index of combination checkpoint blockade in patients with advanced melanoma
GSE335494
Homo sapiens
Expression profiling by high throughput sequencing; Other
44 samples
Submitted 2026/08/07
Platform GPL24676
Summary
Combined checkpoint blockade (CCB) of programmed-death-1 (PD-1) and cytotoxic-T-lymphocyte-associated protein-4 (CTLA-4) is highly active in melanoma but limited by significant morbidity from immune-related adverse events (irAEs). Effective strategies toprevent CCB-mediated irAEs are lacking. Patients with advanced melanoma were randomly assigned to receive standard of care ipilimumab and nivolumab alone (Arm-A: ipi/nivo, n=7) or with one cycle of rituximab (Arm-B; ipi/nivo+rituximab, n=7). Patients receiving ipi/nivo+rituximab experienced lower rates of >grade-3(G3) irAEs (14% versus 57%) and superior G3-irAE-free survival compared to those in ipi/nivo arm (2-year G3- irAE-free survival 86% versus 29% (p=0.01), without adverse impact on tumor regression or survival. Rituximab depleted pre-therapy activated naïve B cells linked to autoimmunity and enhanced CCB-mediated induction of myeloid inflammation and CXCL13+ICOS+ CD4 T cells. B-cell depletion favorably modulates CCB-mediated immune activation and reduces irAE risk.
This dataset
Download
Direct links to NCBI, no account and no request form: the whole study as GSE335494_RAW.tar, processed values as the series matrix, the supplementary file directory, and per-sample supplementary files for any of the 44 samples. Raw sequencing reads are also available from ENA.
Also filed as BioProject PRJNA1478643 and SRA study SRP709746. Searching any of these in the dataset finder brings you back here.
Study design
40 conditions, each sampled once — no replicated groups
Read from the first 40 of 44 sample titles: 40 distinct titles with little repetition. Check it against the sample list below before relying on it.
Samples in this study
0 selected
- GSM9814597 PBMC CITE-seq, S002-A, gene expression (GEX)
- GSM9814598 PBMC CITE-seq, S002-A, antibody-derived tags (ADT)
- GSM9814599 PBMC CITE-seq, S002-B, gene expression (GEX)
- GSM9814600 PBMC CITE-seq, S002-B, antibody-derived tags (ADT)
- GSM9814601 PBMC CITE-seq, S003-A, gene expression (GEX)
- GSM9814602 PBMC CITE-seq, S003-A, antibody-derived tags (ADT)
- GSM9814603 PBMC CITE-seq, S003-C, gene expression (GEX)
- GSM9814604 PBMC CITE-seq, S003-C, antibody-derived tags (ADT)
- GSM9814605 PBMC CITE-seq, S004-A, gene expression (GEX)
- GSM9814606 PBMC CITE-seq, S004-A, antibody-derived tags (ADT)
- GSM9814607 PBMC CITE-seq, S004-B, gene expression (GEX)
- GSM9814608 PBMC CITE-seq, S004-B, antibody-derived tags (ADT)
- GSM9814609 PBMC CITE-seq, S006-A, gene expression (GEX)
- GSM9814610 PBMC CITE-seq, S006-A, antibody-derived tags (ADT)
- GSM9814611 PBMC CITE-seq, S006-C, gene expression (GEX)
- GSM9814612 PBMC CITE-seq, S006-C, antibody-derived tags (ADT)
- GSM9814613 PBMC CITE-seq, S008-A, gene expression (GEX)
- GSM9814614 PBMC CITE-seq, S008-A, antibody-derived tags (ADT)
- GSM9814615 PBMC CITE-seq, S008-C, gene expression (GEX)
- GSM9814616 PBMC CITE-seq, S008-C, antibody-derived tags (ADT)
- GSM9814617 PBMC CITE-seq, S009-A, gene expression (GEX)
- GSM9814618 PBMC CITE-seq, S009-A, antibody-derived tags (ADT)
- GSM9814619 PBMC CITE-seq, S009-B, gene expression (GEX)
- GSM9814620 PBMC CITE-seq, S009-B, antibody-derived tags (ADT)
- GSM9814621 PBMC CITE-seq, S010-A, gene expression (GEX)
- GSM9814622 PBMC CITE-seq, S010-A, antibody-derived tags (ADT)
- GSM9814623 PBMC CITE-seq, S010-BC, gene expression (GEX)
- GSM9814624 PBMC CITE-seq, S010-BC, antibody-derived tags (ADT)
- GSM9814625 PBMC CITE-seq, S012-A, gene expression (GEX)
- GSM9814626 PBMC CITE-seq, S012-A, antibody-derived tags (ADT)
- GSM9814627 PBMC CITE-seq, S012-C, gene expression (GEX)
- GSM9814628 PBMC CITE-seq, S012-C, antibody-derived tags (ADT)
- GSM9814629 PBMC CITE-seq, S013-A, gene expression (GEX)
- GSM9814630 PBMC CITE-seq, S013-A, antibody-derived tags (ADT)
- GSM9814631 PBMC CITE-seq, S013-B, gene expression (GEX)
- GSM9814632 PBMC CITE-seq, S013-B, antibody-derived tags (ADT)
- GSM9814633 PBMC CITE-seq, S014-A, gene expression (GEX)
- GSM9814634 PBMC CITE-seq, S014-A, antibody-derived tags (ADT)
- GSM9814635 PBMC CITE-seq, S014-C, gene expression (GEX)
- GSM9814636 PBMC CITE-seq, S014-C, antibody-derived tags (ADT)
+ 4 more — browse all 44 samples with per-sample file links →
Similar datasets
- GSE318420 Immunosuppressive monocytes are enriched in hepatocellular carcinoma patients with liver dysfunction in a phase II trial of combination sorafenib and nivolumab 210 samples
- GSE272348 Late-stage tertiary lymphoid structures in hepatocellular carcinoma treated with neoadjuvant immune checkpoint blockade 31 samples
- GSE313597 High throughput sequencing of B and T cells in checkpoint inhibitor treated patients 27 samples
- GSE272993 Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8 T cells [dataset 1] 360 samples
- GSE317605 A Phase II Trial of Pembrolizumab plus Granulocyte Macrophage Colony Stimulating Factor in Advanced Biliary Cancer [CITE-Seq] 168 samples
- GSE279392 Single-cell RNA and TCR sequencing from skin, blood and cerebral spinal fluid (CSF) samples from Degos disease patients 116 samples
- GSE309593 Longitudinal Analysis of Multiple Myeloma: Therapeutic Response and Immune Microenvironment Dynamics in the Context of Tumor Heterogeneity [CITE-Seq] 91 samples
- GSE284400 Gene expression and mutation profiles in advanced-stage epithelial ovarian cancer (EOC) 78 samples
Share this dataset
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.